CN110914234A - 抑制ssao/vap-1的胺类化合物及其在医药上的应用 - Google Patents

抑制ssao/vap-1的胺类化合物及其在医药上的应用 Download PDF

Info

Publication number
CN110914234A
CN110914234A CN201880047112.9A CN201880047112A CN110914234A CN 110914234 A CN110914234 A CN 110914234A CN 201880047112 A CN201880047112 A CN 201880047112A CN 110914234 A CN110914234 A CN 110914234A
Authority
CN
China
Prior art keywords
alkylene
radical
atoms
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880047112.9A
Other languages
English (en)
Other versions
CN110914234B (zh
Inventor
顾峥
黎健豪
李峥
王伟华
覃浩雄
崔云增
王绪礼
余淑娜
张英俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN110914234A publication Critical patent/CN110914234A/zh
Application granted granted Critical
Publication of CN110914234B publication Critical patent/CN110914234B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种用于抑制氨基脲敏感性氧化酶(SSAO)和/或血管黏附蛋白‑1(VAP‑1)抑制剂的胺类化合物及其在医药上的应用，进一步涉及含有该胺类化合物的药物组合物。所述的化合物及药物组合物可用于治疗炎症和/或炎症相关疾病、糖尿病和/或糖尿病相关疾病、精神病症、缺血性疾病、血管疾病、纤维化或组织移植排斥。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201880047112.9A 2017-08-04 2018-08-03 抑制ssao/vap-1的胺类化合物及其在医药上的应用 Active CN110914234B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017106594191 2017-08-04
CN201710659419 2017-08-04
PCT/CN2018/098563 WO2019024924A1 (zh) 2017-08-04 2018-08-03 抑制ssao/vap-1的胺类化合物及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN110914234A true CN110914234A (zh) 2020-03-24
CN110914234B CN110914234B (zh) 2023-06-23

Family

ID=65233160

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880047112.9A Active CN110914234B (zh) 2017-08-04 2018-08-03 抑制ssao/vap-1的胺类化合物及其在医药上的应用

Country Status (2)

Country Link
CN (1) CN110914234B (zh)
WO (1) WO2019024924A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109810041A (zh) * 2017-11-21 2019-05-28 南京药捷安康生物科技有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN110719902A (zh) * 2017-06-20 2020-01-21 山东丹红制药有限公司 Ssao抑制剂

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020006177A1 (en) * 2018-06-29 2020-01-02 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
WO2020125776A1 (zh) * 2018-12-20 2020-06-25 山东丹红制药有限公司 式(iv)化合物的工艺路线、晶型及其制备方法
BR112022007974A2 (pt) * 2019-10-29 2022-07-12 Eccogene Shanghai Co Ltd Inibidores de ssao e uso dos mesmos
WO2021258159A1 (en) * 2020-06-26 2021-12-30 Pharmaxis Ltd. Haloallylamine dual amine oxidase inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1921841A (zh) * 2004-02-25 2007-02-28 拉卓拉药物公司 用于治疗疾病的胺和酰胺类化合物
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
CN101917845A (zh) * 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
CN104520268A (zh) * 2012-05-02 2015-04-15 法马克西斯制药公司 Ssao的取代的3-卤代烯丙基胺抑制剂及其用途
CN108341752A (zh) * 2017-01-21 2018-07-31 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1921841A (zh) * 2004-02-25 2007-02-28 拉卓拉药物公司 用于治疗疾病的胺和酰胺类化合物
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
CN101917845A (zh) * 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
CN104520268A (zh) * 2012-05-02 2015-04-15 法马克西斯制药公司 Ssao的取代的3-卤代烯丙基胺抑制剂及其用途
CN108341752A (zh) * 2017-01-21 2018-07-31 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R.B.西尔弗曼编，郭宗儒主译: "《有机药物化学 原著第二版》", 31 January 2008, 化学工业出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110719902A (zh) * 2017-06-20 2020-01-21 山东丹红制药有限公司 Ssao抑制剂
CN110719902B (zh) * 2017-06-20 2022-08-12 山东丹红制药有限公司 Ssao抑制剂
CN109810041A (zh) * 2017-11-21 2019-05-28 南京药捷安康生物科技有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用

Also Published As

Publication number Publication date
WO2019024924A1 (zh) 2019-02-07
CN110914234B (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
CN109988109B (zh) 抑制ssao/vap-1的胺类化合物及其用途
CN109251166B (zh) 抑制ssao/vap-1的胺类化合物及其在医药上的应用
US20220144834A1 (en) Chemical Compounds
US10577367B2 (en) IRAK4 inhibiting agents
CN109988106B (zh) 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109400625B (zh) 稠合双环类化合物及其在药物中的应用
CN110914234A (zh) 抑制ssao/vap-1的胺类化合物及其在医药上的应用
JP7202373B2 (ja) ジヒドロピリミジン化合物、及び医薬におけるその使用
CN109988093B (zh) 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN112789277B (zh) 胍类衍生物及其用途
CN108341752B (zh) 抑制ssao/vap-1的胺类化合物及其在医药上的应用
US20210236493A1 (en) Fused tricyclic compounds and uses thereof in medicine
US11447498B2 (en) Fused tetracyclic compounds and uses thereof in medicine
CN113748104B (zh) 抑制ssao/vap-1的异喹啉酮类化合物及其用途
US20230399332A1 (en) IMIDAZO[1,2-a]PYRAZINE OR PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND USE THEREOF
CN113072476B (zh) RORγt抑制剂及其制备方法和用途
CN111196806B (zh) 胍类衍生物及其用途
CN114728925B (zh) 一种作为ssao/vap-1抑制剂的胺类衍生物及其用途
CN112300211B (zh) 一种作为甲状腺激素β受体激动剂的化合物及其用途
US20230212174A1 (en) Pyrrolo[2,1-f][1,2,4]triazine derivative and use thereof
WO2023160527A1 (zh) 嘧啶并芳香环类化合物及其在药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.